The U.S. FDA approved an expanded use for Merck & Co Inc.'s Capvaxive, making it the only pneumococcal conjugate vaccine approved for children and adolescents (ages 2–17) with chronic conditions who have completed a pneumococcal vaccine series. This decision follows Phase 3 STRIDE-13 data, comparing Capvaxive with PPSV23 in pediatric and adolescent patients at risk for pneumococcal disease. Capvaxive was previously approved for adults (18+) to prevent invasive pneumococcal disease and at-risk patients aged 2–17. The FDA had granted accelerated approval previously.